Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699633 | 0.89 | AKR1C3 (0.48) | AKR1C3SMN1; SMN2LMNAHPGDMAPT | |
| SCHEMBL13699557 | 0.85 | AKR1C3 (0.50) | AKR1C3NPC1RAB9AHRH3USP2 | |
| SCHEMBL13699654 | 0.83 | LTA4H (0.40) | SMN1; SMN2NOTUM | |
| SCHEMBL13699635 | 0.81 | MEN1 (0.41) | — | |
| SCHEMBL13699645 | 0.81 | MEN1 (0.43) | AKR1C3RAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL13699641 | 0.79 | AKR1C3 (0.50) | AKR1C3SMN1; SMN2LMNAHPGDMAPT | |
| SCHEMBL13699638 | 0.76 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2LMNAMAPT | |
| SCHEMBL13699657 | 0.76 | MDM2 (0.44) | AKR1C3LMNAPOLBHPGD | |
| SCHEMBL13699554 | 0.74 | AKR1C3 (0.49) | AKR1C3SMN1; SMN2LMNAMAPK1HPGD | |
| SCHEMBL13699578 | 0.72 | MLNR (0.44) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | AKR1C3 620/4885NPC1 605/4885RAB9A 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.